How the GLP-1/GIP/glucagon triple mechanism works, what phase 2 trials showed, and why researchers are calling it the most potent metabolic peptide studied to date.
Retatrutide is a synthetic peptide designed to simultaneously activate three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This triple-agonist approach builds on the dual GLP-1/GIP mechanism of Tirzepatide by adding a third metabolic lever — glucagon receptor activation — that appears to meaningfully increase energy expenditure and fat breakdown.
The compound is currently in phase 3 clinical development. Phase 2 results published in the New England Journal of Medicine in 2023 generated substantial research interest, reporting weight loss outcomes that exceeded any previously published pharmacological trial.
Each receptor target in Retatrutide's mechanism contributes distinct effects:
Activation of GLP-1 receptors in the hypothalamus reduces appetite and food intake. It also slows gastric emptying (prolonging satiety), stimulates insulin secretion in a glucose-dependent manner, and suppresses glucagon from the pancreas. These are the same core effects seen in Semaglutide and Tirzepatide.
GIP (glucose-dependent insulinotropic polypeptide) enhances the GLP-1 response and appears to reduce gastrointestinal side effects. GIP receptor activation in adipose tissue may also directly improve fat metabolism. This is the same addition that distinguishes Tirzepatide from Semaglutide.
Glucagon is normally known as a hormone that raises blood sugar — the opposite of insulin. However, glucagon receptor activation also has a powerful effect on energy expenditure: it increases thermogenesis (heat production by fat tissue) and directly stimulates the breakdown of stored fat (lipolysis).
The key insight behind Retatrutide's design is that the GLP-1 component prevents the hyperglycemic effect of glucagon, allowing researchers to capture glucagon's energy-expenditure benefits without the unwanted blood sugar elevation. The result is a compound that reduces intake (via GLP-1/GIP) and increases caloric expenditure (via glucagon) — addressing metabolic balance from both sides simultaneously.
A phase 2 randomized controlled trial of Retatrutide in adults with obesity was published in the New England Journal of Medicine in June 2023. The trial enrolled 338 participants and tested multiple dose levels over 48 weeks.
| Dose | Mean Weight Loss (%) | Mean Weight Loss (kg) |
|---|---|---|
| 1mg/week | ~8.7% | ~8.7 kg |
| 4mg/week | ~17.3% | ~17.5 kg |
| 8mg/week | ~22.8% | ~23.0 kg |
| 12mg/week | ~24.2% | ~24.2 kg |
The 24.2% weight loss at the highest dose significantly exceeded results from Tirzepatide (approximately 22.5% in SURMOUNT-1) and Semaglutide (approximately 14.9% in STEP-1). Notably, the weight loss curve at 48 weeks had not yet plateaued, suggesting longer treatment could produce further reduction.
Beyond weight loss, the trial also reported improvements in:
| Compound | Receptor Targets | Peak Trial Weight Loss | Development Stage |
|---|---|---|---|
| Semaglutide | GLP-1 | ~14.9% (STEP-1) | Approved (Ozempic, Wegovy) |
| Tirzepatide | GLP-1 + GIP | ~22.5% (SURMOUNT-1) | Approved (Mounjaro, Zepbound) |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24.2% (Phase 2) | Phase 3 clinical trials |
The progression is striking: each generation of compounds has added a receptor target and produced substantially higher weight loss. The open question for researchers is whether this pattern continues — and whether Retatrutide's phase 3 results will confirm the phase 2 outcomes in a larger population.
Retatrutide entered phase 3 clinical trials following the compelling phase 2 results. Phase 3 trials involve larger patient populations and are designed to confirm safety and efficacy data at scale before regulatory submissions. The compound is under investigation for both obesity and type 2 diabetes indications.
Interest among researchers is high. Retatrutide is one of the most actively searched research peptides in 2025, with growing availability from US-based research suppliers.
See current prices from US research peptide suppliers — sorted by cost per mg.
View Retatrutide Prices →The glucagon receptor component is the key differentiator. While Semaglutide and Tirzepatide reduce caloric intake through appetite suppression, Retatrutide additionally increases energy expenditure through glucagon-driven thermogenesis and lipolysis. This "two-sided" approach to energy balance is what researchers believe drives its superior weight loss outcomes.
Phase 2 data showed a side effect profile broadly similar to other GLP-1 agonists, with nausea, vomiting, and diarrhea being the most common adverse events, predominantly during dose escalation. Heart rate elevations were also observed — a known glucagon effect that is being monitored in phase 3. As with all research peptides, long-term safety data is still accumulating.
As of 2025, Retatrutide is in phase 3 clinical trials. Phase 3 is the final major trial stage before regulatory submission for approval. Given the strength of the phase 2 data, there is significant research and industry interest in the outcomes.
BetterNewLives.com tracks current Retatrutide prices from multiple US research suppliers. See the Retatrutide price comparison page for current supplier pricing and cost-per-mg comparisons.